Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 323

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 323
---
 per share. The Company has designated 10,000 shares of its preferred stock as Series A Convertible Preferred Stock (“Series A Preferred Stock”), 1,000 shares of its preferred stock as Series B Convertible Preferred Stock (“Series B Preferred Stock”), 100,000 shares of its preferred stock as Series C Preferred Stock, and the remainder of the 9,889,000 preferred shares remain authorized but undesignated. As of December 31, 2024, there were 536,908 shares of common stock (which excludes both the 69 unvested shares of restricted stock described in Note 8 below, the 1 share of common stock into which the outstanding shares of Series A Preferred Stock are convertible and does include 12,857 shares of common stock due to exercise of warrants), 17.488 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred Stock issued and outstanding, and a stock payable balance of $0.

 F-9 

During the year ended December 31, 2024, the Company issued a total of 530,971 shares of its common stock, as follows:  Registered offering (described below): ·3,490 shares of its common stock in return for aggregate net proceeds of $728,503 under the Placement Agreement; ·31,666 shares of its common stock upon exercise of pre-funded warrants for aggregate net proceeds of $6,609,831 under the Placement Agreement (includes net proceeds from sale and exercise of pre-funded warrants);   Other issuances: ·68 shares of its common stock upon warrant exercises for aggregate net proceeds of $77,419; ·181 shares of its common stock in return for aggregate net proceeds of $419,967 under the June 2021 ATM Agreement; ·5 shares of its common stock upon conversion of 123.909 shares of its Series A Preferred Stock; and ·46 shares of the previously issued restricted common stock vested. The shares were issued for services and valued at $80,000. ·39 shares of common stock issued as beneficial round up shares as a result of our reverse stock splits   Series B warrant exercises: ·495,476 shares of its common stock upon cashless exercise of Series B Warrants  During the year ended December 31, 2023, the Company issued a total of 4,126 shares of its common stock, as follows:  ·2,464 shares of its common stock